Sigyn Therapeutics (OTCMKTS:SIGY) Issues Earnings Results

Sigyn Therapeutics (OTCMKTS:SIGYGet Free Report) posted its earnings results on Tuesday. The company reported ($2.51) EPS for the quarter, Zacks reports.

Sigyn Therapeutics Stock Performance

SIGY stock opened at $4.15 on Wednesday. The company’s fifty day simple moving average is $4.02 and its 200 day simple moving average is $4.34. Sigyn Therapeutics has a 12-month low of $3.15 and a 12-month high of $6.34.

Sigyn Therapeutics Company Profile

(Get Free Report)

Sigyn Therapeutics, Inc, a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats.

See Also

Earnings History for Sigyn Therapeutics (OTCMKTS:SIGY)

Receive News & Ratings for Sigyn Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sigyn Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.